LBRX
LB Pharmaceuticals Inc
Healthcare · Biotechnology · NGM
$27.80
Close 2026-05-28
✗ NOT SCREENED

UNKNOWN MOAT
MODERATE
Data Confidence: 71%
Some financial metrics pending
Market Cap
$797.2M
Trailing P/E
Forward P/E
-6.19
Rev Growth
Profit Margin
0.0%
ROE
-19.6%
Analyst Target
$38.50
Recommendation
STRONG BUY
About LB Pharmaceuticals Inc

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue RatioN/A
OverallINSUFFICIENT DATA
Score Ethical: 50.0
Score Valuation: 33.0
Score Quality: 21.2
Score Combined: 30.2

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality12.5
Cash Flow50.0
Moat40.0
Balance Sheet68.9
Debt Purity50.0
Liquid Purity50.0
Rev Purity50.0
Compliance100.0
Tier: BRONZE · Score: 42.6 · Rank: #3906
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$427.3M
Price/Book
2.31
Analysts
6
Total Debt
$3.5M
Rec. Mean
1.17
Short Ratio
18.28
Short % Float
0.2%
Employees
35

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 30.2 (P14 — top 86.3% of scored tickers). Unknown Moat. Ethical FAIL. 6 analysts at Strong Buy.
Price: $27.80 | Target: $45.00 (+62%)
Score
30
Moat
Unknown
Conviction
Standard
Upside
+62%
The Fundamentals
Profit Margin0.0%
ROE-19.6%
Forward P/E-6.2
Market Cap$797.2M
Position Sizing Scenarios
Stop: $23.63 (-15%) | Entry: $27.80
SharesCostProfit to TargetR:R
To Consensus ($45.00, 6 analysts)
10$278.00+$172.00 (62%)4.1R
50$1,390.00+$860.00 (62%)4.1R
100$2,780.00+$1,720.00 (62%)4.1R
Risk Factors
  • Elevated short interest (18.28 days to cover)
The Verdict
LB Pharmaceuticals Inc holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
44.8
Risk Grade
Layers
7
Quality: HIGH_SORTINO,LOW_LIQUIDITY
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-6.6%
worst expected daily loss, 19 in 20 days
CVaR 95%
-7.4%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
1.79
above 1.0 is good
Max Drawdown
-17.1%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
35
Liquidity Grade
LOW
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
NONE
Bollinger Position
NEAR_LOWER
Beta
Relative Volume
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
NRIX0.359
NUVL0.329
ABUS0.317
KYMR0.308
SVRA0.308
Inverse Correlated
TickerCorrelation
MGY-0.285
SHEL-0.273
OXY-0.262
BTE-0.252
SATA-0.250
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Monday
Worst Day
Friday
Best Month
Apr
Worst Month
May
Fri-Mon Effect
-2.5911467562571566
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
-12.3%
3M Return
+13.6%
6M Return
+70.6%
12M Return
Momentum Rank
#1151
Momentum Signal
UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access